Available Programs

Treatment selection and modification in MS can be a complex, daunting problem for MS care providers. Enjoy active discussion with your colleagues and get expert insight into optimizing outcomes for your patients on infusible MS therapies! Join us to discuss thought-provoking, real-world cases with your peers and a clinical expert in MS. This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC), the International Organization of Multiple Sclerosis Nurses (IOMSN), and Spire Learning. This activity is supported by…

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a lifetime prevalence of 10% to 20% in children and 1% to 3% in adults. It is the most common pediatric skin disease and primary care providers (PCPs) are often the first point of contact for the diagnosis and management of AD symptoms. As many as 70% of patients with mild to moderate disease can be managed in the primary care setting. This case activity addresses the latest in…

An increasing number of people are taking oral anticoagulants (OACs), and major bleeds or emergent surgeries in these individuals are a challenge to safely and effectively manage. Newer reversal agents that target direct oral anticoagulants have changed the treatment landscape. Clinicians must assess each case and consider the most recent evidence on reversal strategies to recommend an optimal treatment plan. This 30-minute, certified activity will address important clinical issues related to managing bleeds in patients receiving OACs, including evaluating bleed…

Seasonal influenza has a significant socioeconomic impact, with several patient populations at high risk of complications. This podcast will provide the latest updates in the prevention and management of influenza and insights into opportunities for improved patient care, considerations for diagnostic testing, and efficacy and safety of antivirals. https://learning.freecme.com/a/34424P2N9tAD  

Improved understanding of renal cell carcinoma (RCC) has led to the recent approval of immuno-oncology therapies (IOs) that can be used in combination with other IOs or with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). In this interactive webinar experts in RCC discuss IO combinations in RCC, including the rationale for development, clinical trial data, and safety considerations concerning immune-related adverse events. This activity includes interactive polling questions interspersed throughout the activity to engage learners and facilitate application…

Tenosynovial giant cell tumor (TGCT) is a rare, nonmalignant tumor affecting the synovial lining of joints, bursae, and tendon sheaths. It is a potentially locally aggressive disease with high recurrence rates. In addition to agents used off-label for TGCT, the FDA recently approved the first medication specifically indicated for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. This educational activity will ensure clinicians are better informed of the benefits…